schliessen

Filtern

 

Bibliotheken

Safety Assessment of the Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Stable Renal Transplant Recipients

The immunosuppressant mycophenolate mofetil (MMF; CellCept) has greatly improved transplant recipients' clinical outcomes, but its efficacy may be limited by dose adjustments due to adverse events (AEs). An enteric-coated formulation of mycophenolate sodium (EC-MPS; ), designed to improve gastrointe... Full description

Journal Title: Transplantation Proceedings 2005, Vol.37(2), pp.916-919
Main Author: Massari, P
Other Authors: Duro-Garcia, V , Girón, F , Hernández, E , Juárez, F , Castro, C , Toledo, M
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0041-1345 ; E-ISSN: 1873-2623 ; DOI: 10.1016/j.transproceed.2004.12.020
Link: https://www.sciencedirect.com/science/article/pii/S0041134504014587
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_j_transproceed_2004_12_020
title: Safety Assessment of the Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Stable Renal Transplant Recipients
format: Article
creator:
  • Massari, P
  • Duro-Garcia, V
  • Girón, F
  • Hernández, E
  • Juárez, F
  • Castro, C
  • Toledo, M
subjects:
  • Biology
  • Pharmacy, Therapeutics, & Pharmacology
  • Anatomy & Physiology
ispartof: Transplantation Proceedings, 2005, Vol.37(2), pp.916-919
description: The immunosuppressant mycophenolate mofetil (MMF; CellCept) has greatly improved transplant recipients' clinical outcomes, but its efficacy may be limited by dose adjustments due to adverse events (AEs). An enteric-coated formulation of mycophenolate sodium (EC-MPS; ), designed to improve gastrointestinal tolerability is now available. This Latin-American, prospective, multicenter, open-label, 6-month trial assessed the safety and tolerability of converting renal transplant recipients from MMF to EC-MPS. In total, 237 renal transplant recipients (stable ≥ 3 months' posttransplant) receiving MMF (≤1000 mg b.i.d.) were enrolled. Adults (n = 218) were converted to EC-MPS 720 mg b.i.d. (equimolar to MMF 1000 mg b.i.d.) even if they were initially receiving
language: eng
source:
identifier: ISSN: 0041-1345 ; E-ISSN: 1873-2623 ; DOI: 10.1016/j.transproceed.2004.12.020
fulltext: fulltext
issn:
  • 0041-1345
  • 00411345
  • 1873-2623
  • 18732623
url: Link


@attributes
ID245586091
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_j_transproceed_2004_12_020
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_j_transproceed_2004_12_020
sourcesystemPC
dbid
0--K
1--M
2.FO
3.~1
41B1
51P~
61~.
7457
84G.
97-5
108P~
11AABNK
12AAEDT
13AAKOC
14AAOAW
15AAQFI
16ABBQC
17ABMZM
18ABYKQ
19ACDAQ
20ACIUM
21ACRLP
22AEKER
23AEVXI
24AFKWA
25AFTJW
26AFXIZ
27AGHFR
28AGUBO
29AGYEJ
30AIKHN
31AITUG
32AJBFU
33AJOXV
34AJRQY
35AJUYK
36AMFUW
37ANZVX
38BLXMC
39BNPGV
40EO8
41EO9
42EP2
43EP3
44FDB
45FGOYB
46FIRID
47FNPLU
48G-Q
49GBLVA
50J1W
51KOM
52LCYCR
53OAUVE
54OK-
55OW-
56P-8
57P-9
58PC.
59Q38
60R2-
61RPZ
62SCC
63SDF
64SDG
65SDP
66SEL
67SES
68SEW
69SSH
70SSZ
71T5K
72Z5R
73~G-
pqid67770468
galeid196368787
display
typearticle
titleSafety Assessment of the Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Stable Renal Transplant Recipients
creatorMassari, P ; Duro-Garcia, V ; Girón, F ; Hernández, E ; Juárez, F ; Castro, C ; Toledo, M
ispartofTransplantation Proceedings, 2005, Vol.37(2), pp.916-919
identifier
subjectBiology ; Pharmacy, Therapeutics, & Pharmacology ; Anatomy & Physiology
descriptionThe immunosuppressant mycophenolate mofetil (MMF; CellCept) has greatly improved transplant recipients' clinical outcomes, but its efficacy may be limited by dose adjustments due to adverse events (AEs). An enteric-coated formulation of mycophenolate sodium (EC-MPS; ), designed to improve gastrointestinal tolerability is now available. This Latin-American, prospective, multicenter, open-label, 6-month trial assessed the safety and tolerability of converting renal transplant recipients from MMF to EC-MPS. In total, 237 renal transplant recipients (stable ≥ 3 months' posttransplant) receiving MMF (≤1000 mg b.i.d.) were enrolled. Adults (n = 218) were converted to EC-MPS 720 mg b.i.d. (equimolar to MMF 1000 mg b.i.d.) even if they were initially receiving <1000 mg MMF b.i.d. (ie, 47 adults received a higher than equimolar dose of EC-MPS). Children (n = 19) were converted to EC-MPS 450 or 432 mg/m b.i.d. Patients...
languageeng
source
version5
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://www.sciencedirect.com/science/article/pii/S0041134504014587$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Massari, P
1Duro-Garcia, V
2Girón, F
3Hernández, E
4Juárez, F
5Castro, C
6Toledo, M
titleSafety Assessment of the Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Stable Renal Transplant Recipients
description
subject
0Biology
1Pharmacy, Therapeutics, & Pharmacology
2Anatomy & Physiology
general
0English
1Elsevier Inc
210.1016/j.transproceed.2004.12.020
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_j_transproceed_2004_12_020
issn
00041-1345
100411345
21873-2623
318732623
rsrctypearticle
creationdate2005
addtitleTransplantation Proceedings
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
1--M
2.FO
3.~1
41B1
51P~
61~.
7457
84G.
97-5
108P~
11AABNK
12AAEDT
13AAKOC
14AAOAW
15AAQFI
16ABBQC
17ABMZM
18ABYKQ
19ACDAQ
20ACIUM
21ACRLP
22AEKER
23AEVXI
24AFKWA
25AFTJW
26AFXIZ
27AGHFR
28AGUBO
29AGYEJ
30AIKHN
31AITUG
32AJBFU
33AJOXV
34AJRQY
35AJUYK
36AMFUW
37ANZVX
38BLXMC
39BNPGV
40EO8
41EO9
42EP2
43EP3
44FDB
45FGOYB
46FIRID
47FNPLU
48G-Q
49GBLVA
50J1W
51KOM
52LCYCR
53OAUVE
54OK-
55OW-
56P-8
57P-9
58PC.
59Q38
60R2-
61RPZ
62SCC
63SDF
64SDG
65SDP
66SEL
67SES
68SEW
69SSH
70SSZ
71T5K
72Z5R
73~G-
startdate20050101
enddate20051231
lsr40Transplantation Proceedings, 2005, Vol.37 (2), pp.916-919
doi10.1016/j.transproceed.2004.12.020
citationpf 916 pt 919 vol 37 issue 2
lsr30VSR-Enriched:[pqid, galeid]
sort
titleSafety Assessment of the Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Stable Renal Transplant Recipients
authorMassari, P ; Duro-Garcia, V ; Girón, F ; Hernández, E ; Juárez, F ; Castro, C ; Toledo, M
creationdate20050000
lso0120050000
facets
frbrgroupid7837717563416120738
frbrtype5
newrecords20190904
languageeng
topic
0Biology
1Pharmacy, Therapeutics, & Pharmacology
2Anatomy & Physiology
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Massari, P
1Duro-Garcia, V
2Girón, F
3Hernández, E
4Juárez, F
5Castro, C
6Toledo, M
jtitleTransplantation Proceedings
creationdate2005
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Massari
1Duro-Garcia
2Girón
3Hernández
4Juárez
5Castro
6Toledo
aufirst
0P
1V
2F
3E
4C
5M
auinitP
auinit1P
au
0Massari, P
1Duro-Garcia, V
2Girón, F
3Hernández, E
4Juárez, F
5Castro, C
6Toledo, M
atitleSafety Assessment of the Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Stable Renal Transplant Recipients
jtitleTransplantation Proceedings
date2005
risdate2005
volume37
issue2
spage916
epage919
pages916-919
issn0041-1345
eissn1873-2623
formatjournal
genrearticle
ristypeJOUR
abstract
pubElsevier Inc
doi10.1016/j.transproceed.2004.12.020
lad01Transplantation Proceedings